Mutations in the human beta thyroid hormone receptor (h-TR beta) gene are associated with the syndrome of generalized resistance to thyroid hormone. We investigated the interaction of three h-TR beta 1 mutants representing different types of functional impairment (kindreds ED, OK, and PV) with different response elements for 3,3',5-triiodothyronine (T3) and with retinoid X receptor beta (RXR beta). The mutant receptors showed an increased tendency to form homodimers on a palindromic T3-response element (TREpal), a direct repeat (DR + 4), and an inverted palindrome (TRElap). On TRElap, wild type TR binding was decreased by T3, while the mutant receptors showed a variably decreased degree of dissociation from TRElap in response to T3. The extent of dissociation was proportional to their T3 binding affinities. RXR beta induced the formation of h-TR beta 1:RXR beta heterodimers equally well for mutants and the wild type h-TR beta 1 on these T3 response elements. However, the T3-dependent increase in heterodimerization with RXR beta was absent or reduced for the mutant TRs. Transient transfection studies indicated that the dominant negative potency was several-fold more pronounced on the TRElap as compared to TREpal or DR + 4. In CV-1 and HeLa cells, transfection of RXR beta could not reverse the dominant negative action. These results demonstrate that the binding of mutant h-TRs to DNA, as well […] 
Introduction
Mutations in the ligand-binding domain (LBD)' of one allele ofthe human 1 1 thyroid hormone receptor (h-TR, I ) gene can cause the clinical syndromes of generalized resistance to thyroid hormone (GRTH) (1) (2) (3) . This disease is characterized by the refractoriness of tissues to the action of thyroid hormone. However, a marked variability exists in the organ resistance within individuals with GRTH (3) (4) (5) . Intriguingly, the dominant inheritance of the disease is not caused by a lack of active h-TRI3 protein, since heterozygotes with a deleted h-TR1 I allele are clinically and biochemically normal (6) . It has been hypothesized that the mutant h-TR,13 inhibits the function of the normal h-TR by a dominant negative mechanism. This was confirmed by in vitro studies demonstrating that h-TR1 I from patients with mutations in the carboxy-terminal part of the LBD have not only reduced T3-binding and transcriptional activity, but are also able to inhibit normal h-TRa1 and h-TR1 I function in transient transfection systems (7) (8) (9) .
We propose to classify the function of mutant TRs into three different phenomenological types. The type I mutations, represented by kindred ED in this study, have a reduced T3-binding affinity and transcriptional capacity. High levels of T3 can completely normalize TR function and reverse the dominant negative potency. The recently described kindred OK represents a type II mutation. Its T3-binding affinity and transcriptional capacity are reduced, but T3 can neither restore normal TR activity nor reverse the dominant negative potency ( 10) . This mutation therefore impairs independently the T3-binding as well as presumably a transactivating domain, although this latter point needs to be mechanistically proven. Kindred PV represents a type III mutation, which has neither T3-binding nor transcriptional activity, and the dominant negative potency is not reversed by T3.
Three main mechanisms have been proposed to account for the inhibitory property of the three types of mutant h-TR#31: (a) formation of inactive dimers between mutant and normal h-TRs; (b) competition of normal and mutant h-TRs for binding to T3-response elements; and (c) competition for limiting amounts of nuclear auxiliary factors. While the first hypothesis could not be experimentally confirmed, substantial evidence supports a mechanism of competition between mutant and normal receptors for DNA-binding while the role of limiting accessory factors remains equivocal (9, 1 1 ) . One class of these nuclear TR accessory proteins (TRAP) was recently cloned (retinoid X receptor, subtypes a, 13, and y) and shown to be expressed in a tissue-specific manner. RXRs are capable of homodimerizing, as well as of heterodimerizing with TRs, thereby modifying their DNA-binding and transcriptional capacity several-fold (12) (13) (14) (15) (16) (17) (18) (19) (20) (21) . The natural ligand of RXR was recently shown to be an isomer of all-trans-retinoic acid, 9-cisretinoic acid (22, 23) .
The present study was designed to compare the interaction of various mutants and normal h-TR1 I with different positive TREs in the presence and absence of RXRfl. Specifically, we wished to establish whether the dominant negative potency of mutant receptors may be attributed, at least in part, to a preferential binding to DNA and/or RXR,3, as well as to elucidate molecular mechanisms for the intraindividual differences in the tissue-resistance ofpatients with GRTH. While TRE-specific and mutation-specific differences in the DNA-binding and transcriptional characteristics were found, we also demonstrated that competition for limiting amounts ofRXRB did not account for the dominant negative mechanism.
Methods
Construction ofrRXRI3 expression vector. The full-length cDNA for the rat RXRf, was a kind gift of Dr. C. K. Glass, University of California (San Diego, CA) (12) . After excising the rRXR,8 cDNA from pKS-RXRB with EcoRI/BstXI, the ends were blunt-ended with T4 DNA polymerase. HindIll linkers were added and the fragment was ligated into the HindIII site ofthe pSV2 eucaryotic expression vector (9) . The construct was verified by restriction analyses.
In vitro transcription and translation ofreceptors. The construction ofpGEM3 vectors containing the mutant cDNAs for the h-TR# l from kindreds ED and PV was described elsewhere (9) . The vector carrying mutant cDNA from kindred OK was constructed by cloning exon 10 of the h-TR# 1 after amplification by the polymerase chain reaction from genomic DNA into the BglII/HindIII site of pGEM3-h-TR,8l-WT.
The subcloned fragment was sequenced to rule out artifactual muta- (25) except that the protease inhibitors were included in all buffers (1 jtg/ml leupeptin, 1 gg/ml aprotinin, and 0.5 mM phenylmethyl-sulfonylfluoride). From 1 x 108 SF9 cells, 1.5 ml (5 mg/ml protein) of nuclear extracts were obtained. Analysis by gel electrophoresis indicated that RXR,6 accounted for 20-25% of total proteins. The nuclear extracts of wild type SF9 cells were prepared similarly.
Electrophoretic gel mobility shift assay. Single stranded oligonucleotides with sequences shown in Table I were synthesized and purified by high-pressure liquid chromatography. The purified complementary strands were annealed and the ends filled in using Klenow DNA polymerase (Stratagene, San Diego, CA) in the presence of [32p CTP. The labeled double-stranded oligonucleotides were separated on a 12% polyacrylamide gel. The radioactive band was excised and electrotransferred onto DE 81 paper (Whatman Ltd., Maidstone, United Kingdom). The paper was washed with a low salt buffer (10 mM Tris/pH 7.5, 1 mM EDTA, and 0.1 M LiCl), and thereafter, the labeled oligonucleotides were eluted by a high salt buffer ( 10 mM Tris/pH 7.5, 1 mM EDTA, and I M LiCl). After ethanol precipitation, the labeled oligomers were dissolved in a buffer containing 10 mM Tris/pH 7.5 and 1 mM EDTA and stored at -20°C.
The gel mobility shift assay was carried out similarly as described by Yen et al. (26) , except that poly(dI-dC) and bovine serum albumin were omitted, and the concentration of the sheared salmon DNA was increased to 0.8 Mg/MI. Briefly, equal amounts of either in vitro-translated wild type or mutant receptor ( 1-2 gl) were first incubated with the labeled probe ( 10-12,000 cpm) with or without T3 in the binding buffer containing 25 mM Hepes/pH 7.5, 5 mM MgCI2, 4 mM EDTA, 10 mM DTT, 0.1 1 M NaCl, and 0.8 Mg/Ml sheared salmon DNA). Where appropriate, RXRfl (200 ng ofSF9 nuclear extracts) was added. For the control experiments, the nuclear extracts of SF9 cells (200 ng) were added. After incubation for 30 min at 25°C, the mixture was loaded onto a 5.2% polyacrylamide gel and electrophoresed at 4°C for 2-3 h at a constant voltage of 230 V. The gel was dried and subsequently autoradiographed.
Avidin biotin complex DNA binding (ABCD) assay. The protocol is a modification ofa previously published method (27 fl-mercaptoethanol, 1 mM EDTA, 0.1% Nonidet-40, and 20% glycerol (vol/vol). An aliquot of the incubation mixture was transferred to a tube containing 30 Ml streptavidin-agarose slurry. After a 10-min incubation at 4°C, the streptavidin-agarose was quickly washed three times with the above binding buffer at 4°C. The pellet was resuspended in scintillation cocktail and counted. Transient transfection assay. The construction of the wild-type hTRfl1 and mutant pSV2 expression vectors, as well as the chloramphenicol acetyltransferase reporter plasmid containing a TREpal (pMTV-TREpal-CAT) was described before (9, 28) . The pSV2-OK plasmid was obtained by subcloning the insert from pGEM3-OK into the pSV2-WT vector. The pMTV-TRElap-CAT and pMTV-DR+4-CAT plasmids were constructed by cloning a TRElap (5'-AGCTTGA-CCTGACGTCAGGTCAAGCTT-3') or DR+4 (5'-AGCTTAGGT-CACTGGAGGTCAAGCTT-3') oligonucleotide into the HindIII site of pMTV-CAT. The constructs were verified by restriction analyses and sequencing. (29), 100 U/ml penicillin, 100 Ag/ml streptomycin, and 0.25 gg/ml amphotericin B in 10-cm petri dishes (HeLa) or six-well plates (CV-l ) at a density of 1.3 X 106 cells/dish and 0.5 X 10' cells/well, respectively. The medium was changed 4 h before transfection. Using the calcium-phosphate method (CellPhect kit; Pharmacia-LKB, Piscataway, NJ) the cells were transfected with the appropriate plasmids. 24 h later, the plates were washed once with phosphate-buffered saline, and fresh medium was added together with the appropriate T3 concentration. After another 24 h, the cells were harvested, lysed, and the chloramphenicol acetyltransferase activity determined in the extract as described (30) . Chloramphenicol acetyltransferase activity was normalized for the protein concentration as measured by the Coomassie blue method. No substantial differences in the transfection efficiency were present as assessed by the cotransfection of a growth hormone expression vector (pXGH5).
Statistics. Where not indicated otherwise, results were expressed as means±SEM. To examine statistical significance ofthe Scatchard analysis data in Fig. 8 , the slopes of the least square regression lines (with and without T3) were compared by multiple regression analysis with a categorical variable and using an interaction term (SYSTAT 5.03; Systat Inc., Evanston, IL). In the gel mobility shift assay using the TREpal (Fig. 3) or DR+4 (Fig. 4) (Fig. 4, A (Fig. 6 A) . However, no effect of T3 on the binding of h-TR8Il-PV, which is characterized by a non-detectable T3-binding affinity, was observed. The mutants with detectable, but reduced T3-binding showed a moderate degree of dissociation at high levels of T3. When RXR,3 was added, the normal h-TR#3I forms a heterodimer (TR:RXR) and a weaker homodimer (TR:TR) band. Upon addition of T3, the homodimer band further decreases while the heterodimer species increased in a dose-dependent manner (Fig. 6 B) . This increase in the relative amount of heterodimers was virtually absent with the mutant h-TR3l . The possibility of h-TR#3l interacting with an endoge- ( 12, 16) . In this cell line, the T3-dependent transactivation was similar for the TREpal and DR+4 containing reporters (5.9-and 5-fold stimulation, respectively). However, T3 increased the transcription by 25-fold when TRElap was used (Fig. 9) . Cotransfection of an equal amount of pSV2-rRXR,3 inhibited the h-TRfl 1-mediated T3 response by 50% on all three elements.
TRE-dependent dominant negative potency and effect of RXRf. To explain the dominant negative potency of mutant TRs, it has been proposed that mutant and normal receptors may compete for limiting amounts of a nuclear accessory fac- The results are expressed as fold increase of CAT activity in response to T3.
tor (32) . (9) . Although this mutation is located in the ri subdomain that is thought to be involved in the interaction with TRAPs (33, 34) , the h-TRill-ED protein interacted normally with RXR#. The point mutation in the h-TRll of kindred OK reduced T3-binding also fivefold, but high levels of T3 could neither restore full receptor activity nor reverse the dominant negative potency (type II mutation) (10) . Although a defect in the dimerization with RXR/i might explain these characteristics, we now show that this is not the case. Therefore, it can be speculated that this single mutation not only affects the T3-binding, but also a trans-activating domain. The type III mutation studied, h-TRJ I -PV, had a frame-shift mutation in the carboxy terminus ofthe molecule, which is thought to form an amphipathic alpha helix involved in protein-protein contacts (35, 36) . Nevertheless, this mutation which did neither bind T3 nor trans-activate, could interact normally with RXR#. Together with a report that RXR/3 may be a limiting nuclear factor for TR action ( 15, 37) , these findings suggested, that the binding to RXRi might be crucial for the mediation ofthe dominant negative action ofthese receptors. The hypothesis of competition of mutant and normal h-TRs for limiting accessory factors has been proposed before (8, 9, 32) . However, we now report that in a transient transfection system using cell lines with low (CV-1) and high (HeLa) levels of endogenous RXR (12, 14, 16) , the cotransfection of various amounts of RXRf3 could not reverse the dominant negative effect of mutant h-TR#3l.
The DNA-binding affinity ofall three mutant receptors was slightly increased on the rGH promoter. Similarly, these mutants demonstrated a variably increased tendency for homodimerization on the three TREs examined in gel-shift experiments. The degree of increased homodimer formation was not dependent on the type ofTRE, but was rather influenced by the different mutations in the h-TR#3l; the frame-shifted h-TR#l-PV exhibited the most pronounced increase in homodimerization. The influence ofT3 on homodimer formation was dependent on the TRE. While ligand did not influence h-TRf I binding to TREpal, a small or a marked effect was observed on the DR+4 or TRElap, respectively. The binding of TRs to the latter was previously shown to be T3-dependent by Yen et al. (26) . Data from the same group suggested that a type III mutation in codon 345 (kindred Mf) did not dissociate from TRElap in response to T3 (38) . This observation was confirmed for the h-TR#3l-PV using the ABCD assay, where the binding of ligand to normal h-TR#31 decreased the binding affinity for TRElap by threefold, while the affinity of h-TRBl-PV remained unchanged. The type I and II mutations, however, were able to partially dissociate from TRElap in the presence of high levels ofT3. In contrast, T3 could only minimally increase the RXR: TR heterodimer to TR: TR homodimer ratio for these two types of mutations.
It has recently been shown that DNA-binding is required for the dominant negative effect of certain mutations to occur ( 11) . The increased tendency for homodimerization as found in the present study may render the mutant receptors more efficient competitors on dimer-permissive TREs. It can be hypothesized that the dominant negative potency on TRElap-like enhancers such as the myelin basic protein TRE (26, 31, (39) (40) (41) , is even more pronounced because ofthe lack ofligand-induced dissociation of homodimers. This hypothesis was tested and confirmed by transfection studies. While the T3-dependent transcriptional activity ofwild-type h-TRJ l was fivefold higher on the TRElap than on TREpal or DR+4, cotransfection of mutant h-TRf l repressed T3-dependent trans-activation 2.5-fold more efficiently on the TRElap than on the TREpal or DR+4.
Taken together, our observations suggest that mutant h-TR, I inhibit the action of wild-type h-TR mainly by competing for DNA-binding. On TREs where the dissociation of the TRs is ligand induced, the mutant h-TR#l are more effective dominant negative regulators, since they have a higher affinity for the TRE in the presence of T3 than the wild-type h-TR# 1.
While we used the TREpal, DR+4, and TRElap elements as models to study the presumably different binding arrangements of h-TRI:l RXRj3 homo-and heterodimers on DNA (head-to-head, head-to-tail, and tail-to-tail, respectively), it can be speculated that endogenous TREs represent quantitative variations of these themes, subject to the same basic rules established in the present study.
In summary, the functional characteristics of a particular mutant h-TR are not only determined by the type ofthe mutation itself (type I, II, or III), but in addition by the type of the T3-regulated enhancer these receptors are acting on. Assuming that the TREs in the promoter of various organ-specific genes are of different types, it is tempting to speculate that the clinically observed intraindividual differences in organ resistance could be explained in part by the TRE-dependent interaction of mutant receptors with DNA and RXRf3.
